# PANKU-Lung01: HCP commentary report

> 97 verified statements (55 from clinicians verified by NPI or staff page) from 35 commentary sources · 8 findings · commentary checked Nov 4, 2026

## Report

- Trial: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure
- NCT ID: NCT06382116
- Registry: https://clinicaltrials.gov/study/NCT06382116
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: izalontamab brengitecan (BL-B01D1)
- Indication: EGFR-mutated advanced non-small-cell lung cancer after EGFR-TKI failure
- Version: v1.0.0, edition 1
- Accepted: 2026-11-04 UTC
- Last checked: 2026-11-04 UTC
- Release hash: 1adf2eeb25674eac3e49d2c7c45bd4684a406cb14be79cf3c6be697d03da607c

## Counts

- Commentary sources screened: 91
- Sources cited by verified statements: 36
- Verified statements: 97
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 55
- Findings: 8
- Named people in screened sources (unnamed speakers and accounts not counted): 25
- Voices cited: 24
- Cited voices with a verified identity: 20
- Cited clinicians, voices with a confirmed clinical role (the abstract's clinicians): 18
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 18
- By role and specialty (the abstract's specialty counts):
  - 16 physician, Medical oncology
  - 2 physician
- Organisational or shared accounts (not counted as people): 8

A verified identity says who a voice is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified voices without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

PANKU-Lung01 tests whether izalontamab brengitecan (iza-bren) improves progression-free survival versus platinum chemotherapy after EGFR-TKI failure in advanced non-small-cell lung cancer; one clinician would like to use it, while others qualify support. The report cites 18 physicians, including 16 medical oncologists. Debate covers differing interpretations of overall survival and the unsettled order of post-TKI treatments. What combination of mature survival data, patient-reported benefit, workable toxicity management and contemporary comparisons would support local use of iza-bren?

## Open Medical Affairs question

What combination of mature survival, patient-reported benefit, feasible toxicity management and contemporary comparative evidence would make iza-bren a usable option in a particular health system?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. One clinician thinks iza-bren looks like a new standard and would like to use it; others qualify their enthusiasm
- F2. Clinicians flag toxicity and dose-management burden; an episode asks whether the gain is worth it
- F3. Clinicians keep OS provisional, despite one relayed description of improved survival
- F4. Clinicians seek global validation; one challenges the chemotherapy-only comparator
- F5. Clinicians see no settled best sequence among expanding post-TKI options
- F6. Clinicians seek better selection; a discussion leaves targeting versus payload unresolved
- F7. One clinician says diagnostic difficulty and affordability constrain actual treatment choices
- F8. Clinicians see an encouraging read-through to global iza-bren development

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 8 | 6 | 6 | 4 | recorded | 2 |
| F2 | 11 | 9 | 7 | 5 | recorded | 3 |
| F3 | 11 | 13 | 11 | 8 | recorded | 2 |
| F4 | 9 | 8 | 6 | 6 | recorded | 3 |
| F5 | 8 | 8 | 7 | 7 | recorded | 2 |
| F6 | 7 | 4 | 4 | 3 | none recorded | 3 |
| F7 | 3 | 2 | 2 | 2 | none recorded | 2 |
| F8 | 11 | 8 | 8 | 6 | recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 6 | 1 | 0 | 1 | 0 | 11 | 0 | 5 posts and articles, 1 publication | yes |
| F2 | 5 | 1 | 0 | 1 | 4 | 11 | 3 | 5 posts and articles, 1 podcast or video, 1 publication | yes |
| F3 | 4 | 2 | 0 | 2 | 3 | 14 | 1 | 9 posts and articles, 1 podcast or video, 1 publication | yes |
| F4 | 7 | 1 | 0 | 0 | 1 | 9 | 0 | 5 posts and articles, 1 podcast or video | yes |
| F5 | 3 | 5 | 0 | 0 | 0 | 10 | 1 | 7 posts and articles | yes |
| F6 | 6 | 0 | 0 | 0 | 1 | 7 | 3 | 3 posts and articles, 1 podcast or video | yes |
| F7 | 2 | 0 | 1 | 0 | 0 | 3 | 0 | 2 posts and articles | yes |
| F8 | 7 | 1 | 0 | 0 | 3 | 12 | 1 | 7 posts and articles, 1 publication | yes |

### Trial dimensions

- Primary endpoint: Progression-free survival (PFS): F1 (3 shared claims), F2 (3 shared claims), F3 (5 shared claims), F4 (1 shared claims), F6 (1 shared claims), F8 (1 shared claims)
- Secondary endpoints: F1 (3 shared claims), F2 (3 shared claims), F3 (8 shared claims), F4 (2 shared claims), F6 (1 shared claims), F7 (1 shared claims), F8 (1 shared claims)
- Population and setting: F1 (2 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (5 shared claims), F6 (1 shared claims)
- The comparison: F3 (1 shared claims), F4 (3 shared claims), F5 (1 shared claims), F7 (1 shared claims)
- Safety and tolerability: F1 (3 shared claims), F2 (9 shared claims), F3 (2 shared claims), F4 (1 shared claims), F6 (1 shared claims), F7 (1 shared claims)
- Design and conduct: F2 (1 shared claims), F3 (1 shared claims), F4 (1 shared claims), F6 (1 shared claims), F8 (1 shared claims)

## Abbreviations

- EGFR: epidermal growth factor receptor
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival
- PFS: progression-free survival

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. Clinicians flag toxicity and dose-management burden; an episode asks whether the gain is worth it

An AI-voiced podcast asks how to weigh progression-free survival against treatment toxicity with iza-bren.

The episode uses AI-generated voices, not identifiable clinician interviewees.

Source: podcast, 2026-11-02.

### F5. Clinicians see no settled best sequence among expanding post-TKI options

A physician on LinkedIn asks about sequencing antibody-drug conjugates and biomarker-directed treatment after osimertinib.

Source: LinkedIn post, 2026-10-26.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 97 | Paid |
| Who said each statement, with each cited voice's role and what confirmed it (NPI registry or staff page) | 24 | Every edition |
| Trial aspects mapped | 13 | Free |
| Sources with links | 36 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
| Verified speaker IDs as data (NPI, social and scholarly IDs) | 20 | 12-month plan add-on |

Every edition, the free report included, names who said each statement, as the source shows them. Each named voice's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 18 of the 24 cited voices have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, never for outreach or targeting, and it does not unlock who said what.

## Trial aspects

13 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-free survival (PFS) | discussed | 27 | 25 |
| Secondary endpoints | discussed | 23 | 21 |
| Population and setting | discussed | 12 | 7 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 10 | 6 |
| Safety and tolerability | discussed | 23 | 16 |
| Design and conduct | discussed | 6 | 4 |
| Patient-valued benefit and missing quality-of-life evidence | discussed | 3 | 2 |
| Global translatability and contemporary prior treatment | discussed | 12 | 6 |
| Post-TKI sequencing and biomarker-directed alternatives | discussed | 10 | 8 |
| Targeting, payload contribution and predictive biomarkers | discussed | 7 | 4 |
| Brain metastases and intracranial efficacy | discussed | 2 | 2 |
| Diagnostic feasibility, affordability and routine-care access | discussed | 3 | 2 |
| Development outlook and geography-specific treatment positioning | discussed | 21 | 16 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 85 | 32 |
| LinkedIn posts | 3 | 2 |
| Bluesky threads | 2 | 0 |
| Podcasts | 1 | 1 |
| Publications (primary source, cited for context) | not screened | 1 |

- Screened window: 2026-08-18 to 2026-11-03
- Cited window: 2026-08-19 to 2026-11-03
- Retrieved: 2026-11-04

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure
- Registry: NCT06382116 (https://clinicaltrials.gov/study/NCT06382116)
- Study IDs: BL-B01D1-301
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 432 (actual)
- Start: 2024-05-22 (actual)
- Primary completion: 2026-08 (estimated)
- Primary endpoint: Progression-free survival (PFS) (Up to approximately 24 months)
- Intervention: BL-B01D1 (drug)
- Intervention: Pemetrexed+Cisplatin or Carboplatin (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 3 matching sources (3 YouTube videos) could not be read and are not included.
- 1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
- Not yet captured in this edition: a view on the range of treatment options after EGFR-TKI failure.
- Not yet captured in this edition: a view on the global generalizability of post-EGFR-TKI antibody–drug conjugate evidence from China-only trials.
- Not yet captured in this edition: a view on how geographic differences in treatment standards and enrollment complicate future post-EGFR-TKI trial design.
- 68 passages in 61 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 97 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 41 sources about other trials or topics are not included.
- The sources reviewed for this edition are a selected public discussion, not a representative survey of HCPs. Reposts, repeated posts and relays of the same presentation do not establish independent agreement.
- Some potentially relevant passages were not fully assessed, three videos could not be read, and name-focused searches may miss unnamed treatment-decision discussions or transcription variants.
- The podcast uses AI-generated voices. Its discussion cannot be attributed to a named clinician on the basis of editorial involvement.
- Some editorial opinions discussed in the episode are not represented here, which may leave its account of generalizability and future trial design incomplete.
- Several authors' clinical roles are unconfirmed or unstated. Account-level commentary and unconfirmed professional identity do not establish clinician testimony or increase the weight of a statement.
- OS remains immature in the cited accounts, and the episode reports that quality-of-life data were unavailable. These limits prevent the report from resolving the survival and patient-value questions raised by speakers.
- Separate-trial comparisons are not head-to-head evidence. Different safety categories, reported denominators and numerical descriptions are preserved rather than combined.
- No full protocol or exact regulatory label was available to resolve every methodological question or verify indication-specific approval language.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-04 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-04 UTC. No changes.

## Offer

- Size: Focused · 97 verified statements · 55 from 18 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Optional verified speaker identities (12-month updates only, product updates-12-identities; speakers are named and described in every report): the NPI and other verified IDs, to check that each statement is attributed to the right person, never for outreach or targeting, at $15 per identity-verified person in the edition at purchase (20 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/panku-lung01-nct06382116
- Agents: POST https://www.erudio.com/api/orders with {"report": "panku-lung01-nct06382116", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=panku-lung01-06382116

## Cite

Erudio Health. PANKU-Lung01 (NCT06382116): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 4, 2026. https://www.erudio.com/reports/panku-lung01-nct06382116

## Machine access

- JSON: https://www.erudio.com/reports/panku-lung01-nct06382116.json
- Markdown: https://www.erudio.com/reports/panku-lung01-nct06382116.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/panku-lung01-nct06382116/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "panku-lung01-nct06382116"}`